» Articles » PMID: 38548807

Real-time Analysis of Osteoclast Resorption and Fusion Dynamics in Response to Bone Resorption Inhibitors

Overview
Journal Sci Rep
Specialty Science
Date 2024 Mar 29
PMID 38548807
Authors
Affiliations
Soon will be listed here.
Abstract

Cathepsin K (CatK), an essential collagenase in osteoclasts (OCs), is a potential therapeutic target for the treatment of osteoporosis. Using live-cell imaging, we monitored the bone resorptive behaviour of OCs during dose-dependent inhibition of CatK by an ectosteric (Tanshinone IIA sulfonate) and an active site inhibitor (odanacatib). CatK inhibition caused drastic reductions in the overall resorption speed of OCs. At IC CatK-inhibitor concentration, OCs reduced about 40% of their trench-forming capacity and at fourfold IC concentrations, a > 95% reduction was observed. The majority of CatK-inhibited OCs (~ 75%) were involved in resorption-migration-resorption episodes forming adjacent pits, while ~ 25% were stagnating OCs which remained associated with the same excavation. We also observed fusions of OCs during the resorption process both in control and inhibitor-treated conditions, which increased their resorption speeds by 30-50%. Inhibitor IC-concentrations increased OC-fusion by twofold. Nevertheless, more fusion could not counterweigh the overall loss of resorption activity by inhibitors. Using an activity-based probe, we demonstrated the presence of active CatK at the resorbing front in pits and trenches. In conclusion, our data document how OCs respond to CatK-inhibition with respect to movement, bone resorption activity, and their attempt to compensate for inhibition by activating fusion.

Citing Articles

Proteins and DNA Sequences Interacting with Tanshinones and Tanshinone Derivatives.

Szymczyk P, Majewska M, Nowak J Int J Mol Sci. 2025; 26(2).

PMID: 39859562 PMC: 11765770. DOI: 10.3390/ijms26020848.

References
1.
Mulari M, Vaaraniemi J, Vaananen H . Intracellular membrane trafficking in bone resorbing osteoclasts. Microsc Res Tech. 2003; 61(6):496-503. DOI: 10.1002/jemt.10371. View

2.
Runger T, Adami S, Benhamou C, Czerwinski E, Farrerons J, Kendler D . Morphea-like skin reactions in patients treated with the cathepsin K inhibitor balicatib. J Am Acad Dermatol. 2011; 66(3):e89-96. DOI: 10.1016/j.jaad.2010.11.033. View

3.
Aguda A, Panwar P, Du X, Nguyen N, Brayer G, Bromme D . Structural basis of collagen fiber degradation by cathepsin K. Proc Natl Acad Sci U S A. 2014; 111(49):17474-9. PMC: 4267343. DOI: 10.1073/pnas.1414126111. View

4.
Drake M, Clarke B, Oursler M, Khosla S . Cathepsin K Inhibitors for Osteoporosis: Biology, Potential Clinical Utility, and Lessons Learned. Endocr Rev. 2017; 38(4):325-350. PMC: 5546879. DOI: 10.1210/er.2015-1114. View

5.
Li Z, Hou W, Bromme D . Collagenolytic activity of cathepsin K is specifically modulated by cartilage-resident chondroitin sulfates. Biochemistry. 2000; 39(3):529-36. DOI: 10.1021/bi992251u. View